Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds DICE Therapeutics Q2 EPS $(0.58)

DICE Therapeutics Q2 EPS $(0.58)

DICE Therapeutics (NASDAQ:DICE) reported quarterly losses of $(0.58) per share.

byBenzinga Newsdesk

August 11, 2022

1 minute read

DICE Therapeutics (NASDAQ:DICE) reported quarterly losses of $(0.58) per share.

Elon Musk’s Tesla Reportedly Removes Bitcoin As Payment Option, But Keeps Dogecoin

By Mehab Qureshi

July 24, 12:54 AM

Electric vehicle and clean energy company Tesla Inc (NASDAQ:TSLA) has reportedly made changes to its payment page source code, removing Bitcoin (CRYPTO: BTC) while keeping Dogecoin (CRYPTO:

$DOGE

Genpact’s Debt Overview

By Benzinga Insights

January 25, 2:28 PM

Over the past three months, shares of Genpact Inc. (NYSE:G) decreased by 2.68%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.

Ladenburg Thalmann Maintains Buy on Viridian Therapeutics, Raises Price Target to $40

By Benzinga Newsdesk

August 16, 12:01 PM

Ladenburg Thalmann analyst Michael Higgins maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $33 to $40.

VRDN

Legal
News

Histogenics Files For U.S. Patent Titled ‘NEOCARTILAGE CONSTRUCTS USING UNIVERSAL CELLS’

By Benzinga Newsdesk

August 25, 12:33 PM

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220220265900%22.PGNR.&OS=DN/20220265900

HSTO

DICE Therapeutics Q2 EPS $(0.58)

Related Posts

Elon Musk’s Tesla Reportedly Removes Bitcoin As Payment Option, But Keeps Dogecoin

Genpact’s Debt Overview

Ladenburg Thalmann Maintains Buy on Viridian Therapeutics, Raises Price Target to $40

Histogenics Files For U.S. Patent Titled ‘NEOCARTILAGE CONSTRUCTS USING UNIVERSAL CELLS’